Mayo Clinic | Strategic Alliance Partners

December 18, 2019

Matthew P. Goetz, MD, discusses the current treatment landscape for patients with estrogen receptor-positive, HER2-negative breast cancer who harbor ESR1 mutations, and provided an overview of the ELAINE trial.

December 12, 2019

Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer, targeted therapy had an uncertain foothold in this tumor type.

December 05, 2019

Parminder Singh, MD, discusses potential implications of the phase III IMvigor130 trial in advanced bladder cancer.

November 20, 2019

Alan H. Bryce, MD, discusses potential biomarkers of response to immunotherapy in prostate cancer.

November 20, 2019

Erik P. Castle, MD, discusses minimally invasive surgical approaches in renal cell carcinoma.

November 17, 2019

Alan H. Bryce, MD, discusses encouraging updates and emerging strategies in metastatic prostate cancer treatment.

November 14, 2019

Erik P. Castle, MD, discusses the role of cytoreductive nephrectomy in renal cell carcinoma based on interpretation of the CARMENA trial results.

November 13, 2019

Carlos E. Vargas, MD, discusses toxicities associated with stereotactic body radiation therapy compared with standard fractionated radiation therapy in prostate cancer.

November 12, 2019

Thai H. Ho, MD, PhD, discusses frontline treatment considerations in metastatic renal cell carcinoma, the utility of TKI monotherapy, and new combinations on the horizon.

November 12, 2019

Thai H. Ho, MD, PhD, discusses the role of TKI monotherapy in the first-line treatment of patients with metastatic renal cell carcinoma.

November 05, 2019

Alan H. Bryce, MD, discusses how novel agents have impacted the nonmetastatic castration-resistant prostate cancer space.

November 04, 2019

Thai H. Ho, MD, PhD, discusses frontline treatment regimens in metastatic renal cell carcinoma.

October 31, 2019

Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.

October 31, 2019

Shaji K. Kumar, MD, discusses the takeaways from the phase III BELLINI trial which tested venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

October 29, 2019

Parminder Singh, MD, discusses the improvement in overall response rates with immunotherapy, targeted therapy, and antibody-drug conjugates in advanced urothelial cancer.

October 25, 2019

Alan H. Bryce, MD, discusses treatment selection in nonmetastatic castration-resistant prostate cancer.

October 24, 2019

Pashtoon M. Kasi, MD, MBBS, MS, discusses the prognostic value of circulating tumor DNA in colorectal cancer.

October 23, 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the rationale to explore the combination of tucatinib and trastuzumab (Herceptin) in patients with HER2-overexpressing metastatic colorectal cancer.

October 22, 2019

Parminder Singh, MD, discusses combination treatments that are being evaluated in localized bladder cancer.

October 15, 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the results of the phase II BACCI trial evaluating the addition of atezolizumab to capecitabine plus bevacizumab versus capecitabine/bevacizumab plus placebo in patients with microsatellite stable metastatic colorectal cancer.